Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice

被引:144
|
作者
Haberer, Jessica E. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
adherence; preexposure prophylaxis; HIV PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL THERAPY; SELF-REPORT; RISK; MEN; SEX; PREVENTION; INFECTION; TENOFOVIR; INTERVENTIONS;
D O I
10.1097/COH.0000000000000220
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewThe review describes the current understanding of adherence to oral preexposure prophylaxis (PrEP), methods for adherence measurement, approaches to supporting PrEP adherence, and guidance for defining PrEP adherence goals within the larger context of HIV prevention.Recent findingsPrEP adherence has generally been higher in recent trials, open-label extensions, and demonstration projects compared with the initial clinical trials; potential explanations include known PrEP efficacy and different motivations to take PrEP. Recent studies have explored adherence monitoring through electronic pill containers, short message service (SMS), and drug concentrations in hair and dried blood spots. The few PrEP adherence interventions developed to date include combinations of enhanced counseling, feedback of objective adherence measurement, and SMS. Conceptualization of PrEP adherence is evolving. The goal is not 100% adherence indefinitely, as it was in clinical trials. PrEP adherence should be defined with respect to HIV exposure, which varies over time by sexual behavior and use of other prevention strategies.SummaryPrEP adherence beyond clinical trials has generally been high enough to achieve reliable HIV prevention. Future efforts to measure and support PrEP adherence should focus on the context of risk for HIV acquisition, accounting for dynamic behaviors and choices among HIV prevention options.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 50 条
  • [1] Implementing HIV PrEP in Routine Practice
    Sell, Jarrett
    AMERICAN FAMILY PHYSICIAN, 2023, 108 (03) : 227 - 228
  • [2] PrEP implementation: moving from trials to policy and practice
    Caceres, Carlos F.
    O'Reilly, Kevin R.
    Mayer, Kenneth H.
    Baggaley, Rachel
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18 : 1 - 4
  • [3] Unsupervised PrEP in routine practice: a new challenge?
    Laroche, Helene
    Lions, Caroline
    Zaegel-Faucher, Olivia
    Tamalet, Catherine
    Poizot-Martin, Isabelle
    INTERNATIONAL JOURNAL OF STD & AIDS, 2019, 30 (07) : 715 - 717
  • [4] Gender Parity in Clinical PrEP Trials
    Murray, Jeffrey
    Birnkrant, Debra
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (26): : 2584 - 2585
  • [5] VOICE reveals the need to improve adherence in PrEP trials
    Tobin, Stacey C.
    AIDS, 2015, 29 (12) : N9 - N9
  • [6] Pre-exposure prophylaxis (PrEP): review of current clinical practice
    Bradshaw, H.
    Surdhar, S.
    HIV MEDICINE, 2020, 21 : 35 - 35
  • [7] Pre-exposure prophylaxis (PrEP): review of current clinical practice
    Bradshaw, H.
    Yoganathan, K.
    White, R.
    HIV MEDICINE, 2019, 20 : 28 - 28
  • [8] Acceptability in microbicide and PrEP trials: current status and a reconceptualization
    Mensch, Barbara S.
    van der Straten, Ariane
    Katzen, Lauren L.
    CURRENT OPINION IN HIV AND AIDS, 2012, 7 (06) : 534 - 541
  • [9] HIVST a Catalyst for PrEP? Delivery of HIVST for PrEP Users: From Evidence to Practice
    Zulu, Margaret
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 359 - 359
  • [10] Absorbing Markov chain model of PrEP drug adherence to estimate adherence decay rate and probability distribution in clinical trials
    Dale, Renee
    He, Hongyu
    Chen, Yingqing
    JOURNAL OF THEORETICAL BIOLOGY, 2025, 604